Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. - Wikidata - awgldk - TriplyDB

Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.

Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.

http://www.wikidata.org/entity/Q43547830

about

Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential Solvent interaction analysis as a proteomic approach to structure-based biomarker discovery and clinical diagnostics.Greedy feature selection for glycan chromatography data with the generalized Dirichlet distribution Improving N-glycan coverage using HPLC-MS with electrospray ionization at subambient pressure.Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS.Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.Profiling of Endo H-released serum N-glycans using CE-LIF and MALDI-TOF-MS--application to rheumatoid arthritis.Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer.N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation.Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer Decreased core-fucosylation contributes to malignancy in gastric cancer.Development of recombinant Aleuria aurantia lectins with altered binding specificities to fucosylated glycans.Large-scale identification of core-fucosylated glycopeptide sites in pancreatic cancer serum using mass spectrometry.Mature N-linked glycans facilitate UT-A1 urea transporter lipid raft compartmentalization.N-Glycan profiling of dried blood spots Examination of glycan profiles from IgG-depleted human immunoglobulins facilitated by microscale affinity chromatography.Glycosylation status of serum immunoglobulin G in patients with prostate diseases.Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma.Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue Analytical glycobiology at high sensitivity: current approaches and directions Intrinsic hepatocyte dedifferentiation is accompanied by upregulation of mesenchymal markers, protein sialylation and core alpha 1,6 linked fucosylation Enrichment strategies in glycomics-based lung cancer biomarker development.Biomarkers of Helicobacter pylori-associated gastric cancer.Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.Aberrant PSA glycosylation--a sweet predictor of prostate cancer.NMR and Molecular Recognition of N-Glycans: Remote Modifications of the Saccharide Chain Modulate Binding Features.Relative versus absolute quantitation in disease glycomics.Glycosylation and liver cancer.Sialic acids: biomarkers in endocrinal cancers.Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer Sialylation: an Avenue to Target Cancer Cells.Site-Specific Fucosylation Analysis Identifying Glycoproteins Associated with Aggressive Prostate Cancer Cell Lines Using Tandem Affinity Enrichments of Intact Glycopeptides Followed by Mass Spectrometry The role of glycans in the development and progression of prostate cancer.Can glycoprofiling be helpful in detecting prostate cancer?Glycans and glycoproteins as specific biomarkers for cancer.Biological functions of fucose in mammals.

P2860

Q26748089-077F49E7-77FB-4B97-A966-F2518536B050 Q26750872-D504AC59-7DD9-4A3F-B97D-4B9B7924F2F2 Q26778227-CA175CCF-FD9C-4891-8646-0AD7D1C840D7 Q27022638-E7379ABB-14E5-4178-8889-79F871D984D8 Q30381260-D050B2AD-09BE-401C-8327-D692055961D5 Q30621928-9BB9AEE7-5BCB-48B6-9C97-63254B61F1BC Q33456015-5EE48B3C-CA3E-42E9-8575-BA2147B8E55C Q33671429-4D995C0F-7405-41B7-A69B-4761F922C8D2 Q33688938-46DE60FF-CB87-44FD-A1A2-2CC8D678F198 Q34105028-D4B345EC-AE95-4674-9359-5EA2C9D18E25 Q34129290-81904A48-D7DC-4E73-B570-4E464A533B8A Q34264310-ACC5E451-AFB8-4EEC-9021-B1F4F8205C26 Q34785893-E72E72C8-3DB5-4063-B0AA-718D7BDF3A68 Q35065968-C324DABA-BF52-464C-9B8E-09C1A0BE545E Q35147774-83BF15AF-101F-4AD3-9D7C-AF2E145FA015 Q35450855-7757192E-EF15-4B67-B44D-3CF0FEE23147 Q35542255-F59937B2-5920-43DC-BA1C-699BCAA464E5 Q35609590-199BA23D-F88C-443B-9021-8DA6B76474C3 Q35675417-4BBBCDB3-F8E2-432F-90D9-B0C35B3CB281 Q35874074-7D778678-6D35-4E76-B8AA-48D54D31BE50 Q35924714-98D03DD9-75E3-4718-B8F0-0448939F7F2C Q36155480-0E4C2B37-0220-4FFB-BA7F-CB038A6D628B Q36278033-B301E149-A76F-4CC4-9081-FA4BE31F88C4 Q36651493-0559844E-2BF0-4AB0-9DD5-05FC531DC175 Q37027426-39234B07-0C2A-4C27-97D9-10C82750C200 Q37446239-04EBEBCE-5011-42BC-B7AD-22432725B135 Q37591506-34D51C0F-9A68-4D36-8BF5-2E1479F8B37A Q37672628-FBE86BDD-D0B8-43A0-BFA0-B30D4C37F6E1 Q38074010-61BDCF59-2C0B-49FE-AEE8-8CB268E5C307 Q38289075-E40DA086-5F10-4013-9578-F21FC8192342 Q38356585-7F175AA5-67D5-4EED-B780-2893E991A40E Q38366329-99A59220-1C7E-498C-9D9B-287180682187 Q38380548-211EBE42-FD64-4DCF-BF44-6114C3DB9BDA Q38544783-57EADA50-1242-4E7B-B6F2-025C85C4A116 Q38674223-EF5F90B4-E947-4D41-AF46-BCE83913617F Q38719466-3A80DB6B-FA53-434C-B8A3-84147D574DB3 Q38811520-5C06A6AB-9F1F-4BD5-A90F-5117BF172FF3 Q38852467-4B5738AF-9403-443F-B385-D8C219D98AF5 Q38945184-9A6F683F-0839-444E-9615-FE69B99C44A5 Q39254939-51EF409F-0670-4A03-A768-DA757EFD34A5

P2860

Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.

http://www.wikidata.org/entity/Q43547830

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Core fucosylation and alpha2-3 ...... o benign prostate hyperplasia.

@en

Core fucosylation and alpha2-3 ...... o benign prostate hyperplasia.

@nl

type

label

Core fucosylation and alpha2-3 ...... o benign prostate hyperplasia.

@en

Core fucosylation and alpha2-3 ...... o benign prostate hyperplasia.

@nl

prefLabel

Core fucosylation and alpha2-3 ...... o benign prostate hyperplasia.

@en

Core fucosylation and alpha2-3 ...... o benign prostate hyperplasia.

@nl

P1433

Q43547830-9F936995-64F4-4B92-81BB-2138EBEC319A

P1476

Q43547830-C0BA9818-9A74-4CB1-9EEB-397FBEE6C167

P2093

Q43547830-11B1B236-B413-4F56-BEED-BDB43831A855

Q43547830-511945E6-E0A9-41A9-A764-7E94A1B3D0AA

Q43547830-EDDFF975-C1FF-4FB3-AE5B-818096CAFB4D

Q43547830-FC21D340-0ACF-490C-80DF-35D4A08FEF96

P2860

Q43547830-0007E2D7-2D90-4A7E-A50C-2F6FCCC09128

Q43547830-0CEA7B4E-74C5-4248-8027-41F5E2CAE165

Q43547830-0E40D0A0-6EF0-4E3A-B4B3-2C91906080E2

Q43547830-17F0070F-60F8-438E-AA9D-D960C348C262

Q43547830-1BA4521C-2695-4A8C-87C4-FD73DA6FA7BC

Q43547830-2F55C08B-12BF-49AD-84F6-3AA58A4E73B6

Q43547830-39816E92-EEF0-4FF0-9837-B82EC2E44A92

Q43547830-40F65245-65E6-4A5C-8E82-030A366128C7

Q43547830-4B78C9A0-9B76-4E18-B48E-3D158B2C9F45

Q43547830-62501ED5-0388-4799-934C-4630623C3216

P304

Q43547830-4E378968-2515-479B-B79C-521A087A7A06

P31

Q43547830-C27D0329-38F2-4C61-91E0-44387AD13E30

P356

Q43547830-087D4178-9C2E-412E-92E4-84FC2EE8FE87

P433

Q43547830-546311CE-E5CC-4E9D-A20D-52F96406EB21

P478

Q43547830-2A20DB03-9894-4752-B4DC-CF6C72FADB92

P50

Q43547830-3750D0A0-8E63-42BE-BAEC-4A03332ECDBA

P577

Q43547830-D9853524-72ED-46D9-8D75-B1A454D7AA98

P5875

Q43547830-BB8DDA7C-6157-4664-82DA-0D53FB2B6672

P698

Q43547830-B40223D6-584F-4DC0-9673-3CFF061E0170

P356

P1433

P1476

Core fucosylation and alpha2-3 ...... to benign prostate hyperplasia

@en

P2093

John M Fitzpatrick

http://www.w3.org/2001/XMLSchema#string

Pauline M Rudd

http://www.w3.org/2001/XMLSchema#string

Radka Saldova

http://www.w3.org/2001/XMLSchema#string

Yue Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Growth and survival mechanisms associated with perineural invasion in prostate cancer

Cancer statistics, 2009

Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.

digeR: a graphical user interface R package for analyzing 2D-DIGE data.

Glycan characterization of PSA 2-DE subforms from serum and seminal plasma.

Estimates of cancer incidence and mortality in Europe in 2008.

Expression of alpha1,6-fucosyltransferase (FUT8) in papillary carcinoma of the thyroid: its linkage to biological aggressiveness and anaplastic transformation.

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid.

Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation.

P304

195-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/GLYCOB/CWQ147

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Ronald William Watson

P577

2010-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46403118

http://www.w3.org/2001/XMLSchema#string

P698

20861084

http://www.w3.org/2001/XMLSchema#string